
Opinion|Videos|March 19, 2025
New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study
Panelists discuss how the HERIZON-BTC-302 study demonstrated zanidatamab's efficacy in HER2-positive biliary tract cancer (BTC) with key end points presented at ASCO GI, while sharing insights on optimal dosing strategies and early real-world experience with this newly approved agent in the second-line setting.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Zanidatamab was recently approved. What were some key end points from the HERIZON-BTC-302 study at ASCO GI and what are your impressions?
- What is your dosing strategy with zanidatamab? Dr Ellis, can you share some highlights from a poster looking at optimizing zanidatamab’s dosing?
- For those with experience using zanidatamab in the 2L, what has your experience been? What outcomes have you seen in patients so far?
Advertisement
Related to this article

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
3
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
4
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
5


